Dr. Janina Baranowska-Kortylewicz received her MSc from Wrocław University of Science and Technology (Politechnika Wrocławska) in Wrocław, Poland, and her doctorate from the University of Kentucky in Lexington, KY, USA. She continued her postgraduate research at the Albert B. Chandler Medical Center and Harvard Medical School. She is currently a professor at the College of Pharmacy, University of Nebraska Medical Center. For over 15 years, she directed the UNMC Harry J. Bahr Radiolabeling Facility, where, under her supervision, radioactive drugs and radioimmunoconjugates were prepared for clinical studies. Her research activities are focused on the design, synthesis, and evaluation of theranostics, i.e., radioactive drugs for the targeted molecular radiotherapy and noninvasive diagnosis of cancer, as well as on the identification of tumor-specific targets and development of theranostics to these new targets. She holds several U.S. and international patents. The Investigational New Drug application for the clinical use of one of the radioactive drugs discovered and developed in her laboratories was allowed by the FDA. She is a member of the editorial boards of several international journals and is a member of national and international scientific organizations. Her expertise in the development of a new radioactive drug and the translational sciences earned her a place on several grant review panels.